Tanios S. Bekaii-Saab, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for early- and intermediate-stage hepatocellular carcinoma.
EMA Validates Application for Nivolumab/Ipilimumab in Liver Cancer Type
Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Lunresertib Combo Shows Responses in Advanced Pretreated GI Cancer Subtypes
Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
Toripalimab Combo May Improve Survival Vs Sorafenib in Advanced HCC
Investigators of the HEPATORCH trial will present additional data on toripalimab plus bevacizumab in this population at a future academic conference.
Antitumor Activity Seen With Olverembatinib in GIST Subtype
Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.